One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. We offer an array of women’s health products, and our intention is to assist our partners with the different challenges that mature products may present.
In this respect, we are pleased to announce the successful pivotal BE results of two products within this domain.
• Drospirenone + Ethinylestradiol has been developed based on the reference brand Yasmin. The INN sold approximately $811 mio globally in 2021, according to IQVIA. We are preparing for DCP submission, which is scheduled for December 2022.
• Desogestrel + Ethinylestradiol has been developed based on the reference brand Marvelo. The INN sold approximately $336 mio globally in 2021, according to IQVIA. We are preparing for DCP submission, which is scheduled for March 2023.
Both products are low dose oral contraceptives.
Adalvo has embarked on a strategic collaboration with a partner that specializes in this domain and is offering a basket of additional hormonal products, that will enable our partners to offer a wide array of oral contraceptive and hormonal replacement products, at a global level.
